000			02112 a2200589 4500
005			20250515155243.0
264		0	_c20090611
008			200906s 0 0 ger d
022			_a1438-8820
024	7		_a10.1055/s-0028-1098786 _2doi
040			_aNLM _beng _cNLM
100	1		_aMiller, K
245	0	0	_a[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. _h[electronic resource]
260			_bAktuelle Urologie _cJan 2009
300			_a27-30 p. _bdigital
500			_aPublication Type: Comparative Study; Consensus Development Conference; Journal Article
650	0	4	_aAngiogenesis Inhibitors _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aAntineoplastic Agents _xadministration & dosage
650	0	4	_aBenzenesulfonates _xadministration & dosage
650	0	4	_aBevacizumab
650	0	4	_aCarcinoma, Renal Cell _xdrug therapy
650	0	4	_aChemotherapy, Adjuvant
650	0	4	_aClinical Trials, Phase II as Topic
650	0	4	_aClinical Trials, Phase III as Topic
650	0	4	_aHumans
650	0	4	_aIndoles _xadministration & dosage
650	0	4	_aKidney _xpathology
650	0	4	_aKidney Neoplasms _xdrug therapy
650	0	4	_aNeoadjuvant Therapy
650	0	4	_aNeoplasm Metastasis
650	0	4	_aNephrectomy
650	0	4	_aNiacinamide _xanalogs & derivatives
650	0	4	_aPhenylurea Compounds
650	0	4	_aProtein Kinase Inhibitors _xadministration & dosage
650	0	4	_aPyridines _xadministration & dosage
650	0	4	_aPyrroles _xadministration & dosage
650	0	4	_aRisk Assessment
650	0	4	_aRisk Factors
650	0	4	_aSirolimus _xadministration & dosage
650	0	4	_aSorafenib
650	0	4	_aSunitinib
650	0	4	_aTime Factors
700	1		_aBergmann, L
700	1		_aJäger, E
700	1		_aJakse, G
700	1		_aWirth, M
700	1		_aKeilholz, U
773	0		_tAktuelle Urologie _gvol. 40 _gno. 1 _gp. 27-30
856	4	0	_uhttps://doi.org/10.1055/s-0028-1098786 _zAvailable from publisher's website
999			_c18623142 _d18623142